The role of mineralocorticoid receptor function in treatment-resistant depression

Journal of Psychopharmacology

Volumn 27, Issue 12, 2013, Pages 1169-1179

  Juruena, Mario F ^a,b,c   Pariante, Carmine M ^a   Papadopoulos, Andrew S ^b   Poon, Lucia ^b   Lightman, Stafford ^d   Cleare, Anthony J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BETHLEM ROYAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cortisol; hypothalamic pituitary adrenal axis; mineralocorticoid receptor; mineralocorticoid receptor antagonist; prednisolone; treatment resistant depression

Indexed keywords

CANRENONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PREDNISOLONE; SPIRONOLACTONE; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE DETERMINATION; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; METABOLITE; MOLECULAR PATHOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; SALIVA LEVEL; TREATMENT RESISTANT DEPRESSION; UPREGULATION; CASE CONTROL STUDY; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SALIVA; SINGLE BLIND PROCEDURE;

CANRENONE; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; PREDNISOLONE; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; SALIVA; SINGLE-BLIND METHOD; SPIRONOLACTONE;

EID: 84887845694     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113499205     Document Type: Article

References (61)

1. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press ; 1994:
2. Arvat E, Maccagno B, Giordano R, et al. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab. 2001 ; 86: 3176-3181
3. Barden N, Stec IS, Montkowski A, et al. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology. 1997 ; 66: 212-220
4. Bauer ME, Papadopoulos A, Poon L, et al. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology. 2003 ; 28: 49-65
5. Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 ; 67: 588-597
6. Bifulco A, Bernazzani O, Moran PM, et al. The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series. Br J Clin Psychol. 2005 ; 44: 563-581
7. Bifulco A, Brown GW, Harris TO. Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry. 1994 ; 35: 1419-1435
8. Catalan R, Gallart JM, Castellanos JM, et al. Plasma corticotropin- releasing factor in depressive disorders. Biol Psychiatry. 1998 ; 44: 15-20
9. Cornelisse S, Joels M, Smeets T. A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory. Neuropsychopharmacology. 2011 ; 36: 2720-2728
10. De Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005 ; 6: 463-475
11. De Kloet ER, Vreugdenhil E, Oitzl MS, et al. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998 ; 19: 269-301
12. Deuschle M, Weber B, Colla M, et al. Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans. Neuroendocrinology. 1998 ; 68: 355-360
13. Dodt C, Kern W, Fehm HL, et al. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology. 1993 ; 58: 570-574
14. First MB, Spitzer RL, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R Personality-Disorders (SCID-II) 2. Multisite test-retest reliability study. J Personal Disord. 1995 ; 9: 92-104
15. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for DSM-IV Axis I Disorders- Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press ; 1997:
16. Flores BH, Kenna H, Keller J, et al. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006 ; 31: 628-636
17. Grossmann C, Freudinger R, Mildenberger S, et al. Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am J Physiol Renal Physiol. 2004 ; 286: F1226 - F1231
18. Grottoli S, Giordano R, Maccagno B, et al. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab. 2002a ; 87: 4616-4620
19. Grottoli S, Maccagno B, Ramunni J, et al. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J Endocrinol Invest. 2002b ; 25: 420-425
20. Halbreich U, Asnis GM, Shindledecker R, et al. Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry. 1985 ; 42: 909-914
21. Heuser I, Deuschle M, Weber B, et al. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology. 2000 ; 25: 513-518
22. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999 ; 33: 181-214
23. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000 ; 23: 477-501
24. Joels M, Karst H, DeRijk R, et al. The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 2008 ; 31: 1-7
25. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr. 2004 ; 26: 189-201
26. Juruena MF, Cleare AJ, Papadopoulos AS, et al. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology. 2006 ; 189: 225-235
27. Juruena M, Pariante C, Papadpoulos A, et al. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry. 2009 ; 194: 342-349
28. Juruena M.F, Pariante CM, Papadopoulos A, et al. The development and application of the prednisolone suppression test in psychiatry: a novel tool for assessing glucocorticoid and mineralocorticoid receptor function. Mind Brain. 2010a ; 1: 115-122
29. Juruena MF, Cleare AJ, Papadopoulos AS, et al. The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment. Psychoneuroendocrinology. 2010b ; 35: 1486-1491
30. Kellner M, Baker DG, Yassouridis A, et al. Mineralocorticoid receptor function in patients with posttraumatic stress disorder. Am J Psychiatry. 2002 ; 159: 1938-1940
31. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology. 1994 ; 19: 313-333
32. Kocarek TA, Schuetz EG, Strom SC, et al. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos. 1995 ; 23: 415-421
33. Kuningas M, De Rijk RH, Westendorp RG, et al. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. Neuropsychopharmacology. 2007 ; 32: 1295-1301
34. Lembke A, Gomez R, Tenakoon L, et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology. 2013 ; 38: 115-121
35. Lopez JF, Chalmers DT, Little KY, et al. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry. 1998 ; 43: 547-573
36. McEwen BS. Allostasis and allostatic load: Implications for neuropsychopharmacology. Neuropsychopharmacology. 2000 ; 22: 108-124
37. Markopoulou K, Papadopoulos A, Juruena MF, et al. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology. 2009 ; 34: 19-26
38. Nishi M, Kawata M. Dynamics of glucocorticoid receptor and mineralocorticoid receptor: implications from live cell imaging studies. Neuroendocrinology. 2007 ; 85: 186-192
39. O'Keane V, Dinan TG, Scott L, et al. Changes in hypothalamic-pituitary- adrenal axis measures after vagus nerve stimulation therapy in chronic depression. Biol Psychiatry. 2005 ; 58: 963-968
40. Oshima A, Yamashita S, Owashi T, et al. The differential ACTH responses to combined dexamethasone/CRH administration in major depressive and dysthymic disorders. J Psychiatr Res. 2000 ; 34: 325-328
41. Otte C, Hinkelmann K, Moritz S, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010 ; 44: 339-346
42. Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact. 1987 ; 5: 273-302
43. Pace TW, Spencer RL. Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor. Am J Physiol Endocrinol Metab. 2005 ; 288: E1082 - E1088
44. Pariante CM, Papadopoulos AS, Poon L, et al. A novel prednisolone suppression test for the hypothalamic-pituitary- adrenal axis. Biol Psychiatry. 2002 ; 51: 922-930
45. Pfohl B, Sherman B, Schlechte J, et al. Differences in plasma ACTH and cortisol between depressed patients and normal controls. Biol Psychiatry. 1985 ; 20: 1055-1072
46. Reul JM, Gesing A, Droste S, et al. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol. 2000 ; 405: 235-249
47. Reul JMHM, De Kloet ER. Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation. Endocrinology. 1985 ; 117: 2505-2511
48. Ribeiro SC, Tandon R, Grunhaus L, et al. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry. 1993 ; 150: 1618-1629
49. Rupprecht R, Reul JM, Van Steensel B, et al. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 ; 247: 145-154
50. Russell GM, Henley DE, Leendertz J, et al. Glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 ; 30: 6106-6115
51. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 ; 285: 1299-1307
52. Schuetz EG, Brimer C, Schuetz JD. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol. 1998 ; 54: 1113-1117
53. Spencer RL, Kim PJ, Kalman BA, et al. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology. 1998 ; 139: 2718-2726
54. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997 ; 58: 23-29
55. Watson S, Gallagher P, Del-Estal D, et al. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med. 2002 ; 32: 1021-1028
56. Wellhoener P, Born J, Fehm HL, et al. Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. J Clin Endocrinol Metab. 2004 ; 89: 5048-5052
57. Williams JBW Structured Interview Guide for the Hamilton-Depression And Anxiety Scales (SIGH-AD). New York: New York State Psychiatric Institute: ; 1988:
58. Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004 ; 29: 1538-1545
59. Young EA, Lopez JF, Murphy-Weinberg V, et al. The role of mineralocorticoid receptors in hypothalamic-pituitary- adrenal axis regulation in humans. J Clin Endocrinol Metab. 1998 ; 83: 3339-3345
60. Young EA, Lopez JF, Murphy-Weinberg V, et al. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry. 2003 ; 60: 24-28
61. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 ; 29: 687-710